Anteris

Anteris Technologies Ltd (formerly known as Admedus (formerly known as Allied Healthcare Group Ltd), through its subsidiary Admedus Vaccines (formerly Coridon)), is a structural heart company delivering clinically superior solutions, focused on the development of next-generation technologies with world class partners.In July 2010, Australian medical devices company, Allied Medical, planned to acquire a 38.6% controlling stake in Coridon via a AUD $3 million (US $2.6 million) rights issue. Under the agreement, Allied Medical could acquire up to 55.7% interest. In June 2011 BioMD and Allied Medical Ltd were merged to form Allied Healthcare Group. In April 2012, Allied Healthcare held a 44% stake in Coridon. In July 2013, Allied Healthcare increased the stake in Coridon from 44 to 50.1%.In February 2023, Anteris Technologies Ltd completed equity fundraising, as a result of which the company issued 1.458 million new ordinary shares at an issue price of $24.00

About Serina Therapeutics Serina is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina’s POZ PlatformTM delivery technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (“PEG”) and other biocompatible polymers. Our POZ PlatformTM partners are at the forefront in advancing LNP delivery technology to develop novel RNA therapeutics. Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://serinatherapeutics.com. About AgeX AgeX has been focused on developing and commercializing innovative therapeutics to treat human diseases to increase health span and combat the effects of aging. For more information, please visit http://agexinc.com. August 30, 2023 – Serina Therapeutics, Inc. (“Serina”) entered into a merger agreement with AgeX Therapeutics, Inc. (NYSE American: AGE) (“AgeX”) on August 29, 2023, under which Serina will merge with a wholly-owned subsidiary of AgeX in an all-stock transaction. Upon completion of the transaction, the combined company will operate under the Serina Therapeutics name, and the combined company’s common stock is expected to trade on the NYSE American under the ticker symbol “SER.” The corporate headquarters will be in Huntsville, Alabama.

Forte Biosciences, Inc.是一家临床阶段的皮肤病学公司，致力于开发用于治疗炎症性皮肤病的活体生物疗法FB-401。 FB-401已完成对成人和儿童（3岁及以上）特应性皮炎患者的1/2a期测试。 对于安全和有效的疗法，特别是对于小儿特应性皮炎患者，存在大量的需求。Forte计划在2020年代中期将FB-401推进到2期临床试验中。